Holen Sie sich die Stockscreener-App
0.7165
11.79%
-0.0965
Schlusskurs vom Vortag:
$0.813
Offen:
$0.81
24-Stunden-Volumen:
52,213
Relative Volume:
0.35
Marktkapitalisierung:
$36.40M
Einnahmen:
$2.72M
Nettoeinkommen (Verlust:
$-85.08M
KGV:
-0.3712
EPS:
-1.93
Netto-Cashflow:
$-70.93M
1W Leistung:
-32.02%
1M Leistung:
-41.70%
6M Leistung:
-41.22%
1J Leistung:
-92.27%
1-Tages-Spanne:
$0.71
$0.81
1-Wochen-Bereich:
$0.71
$1.05
52-Wochen-Spanne:
$0.71
$11.76
Shattuck Labs Inc Stock (STTK) Company Profile
Firmenname
Shattuck Labs Inc
Sektor
Branche
Telefon
512-900-4690
Adresse
500 W. 5TH STREET, AUSTIN
Vergleichen Sie STTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
0.71 | 36.40M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.81 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.50 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
559.07 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.92 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
239.78 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-02 | Herabstufung | Needham | Buy → Hold |
| 2024-10-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-08-31 | Eingeleitet | BTIG Research | Buy |
| 2022-06-01 | Eingeleitet | Citigroup | Buy |
| 2022-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2021-01-11 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-03 | Eingeleitet | Citigroup | Buy |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Needham | Buy |
Alle ansehen
Shattuck Labs Inc Aktie (STTK) Neueste Nachrichten
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference - TradingView
24,446 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Virtu Financial LLC - Defense World
STTK stock plunges to 52-week low, touches $0.93 - Investing.com
Brokers Issue Forecasts for Shattuck Labs Q1 Earnings - Defense World
515,619 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Takeda Pharmaceutical Co. Ltd. - MarketBeat
H.C. Wainwright holds Shattuck Labs stock at Neutral - Investing.com
Shattuck Labs Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Shattuck Labs (NASDAQ:STTK) Given Neutral Rating at HC Wainwright - Defense World
Shattuck Labs’ (STTK) “Hold” Rating Reaffirmed at Needham & Company LLC - Defense World
Shattuck Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Shattuck Labs Inc (STTK) Q4 2024 Earnings: EPS of -$0.37 Misses Estimate, Revenue of $0.71M Below Expectations - GuruFocus
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 - Nasdaq
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business - Bluefield Daily Telegraph
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, TLS and ASTR - ACCESS Newswire
Leerink Partnrs Forecasts Shattuck Labs FY2024 Earnings - Defense World
Brokerages Set Shattuck Labs, Inc. (NASDAQ:STTK) Target Price at $7.50 - Defense World
Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs - Defense World
Shattuck Labs (NASDAQ:STTK) Coverage Initiated by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Shattuck Labs (STTK) with Outperform Recommendation - Nasdaq
Leerink initiates Shattuck Labs stock with Outperform, $4 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Shattuck Labs at Outperform With $4 Price Target -March 17, 2025 at 07:39 am EDT - MarketScreener
Stocks Recover Some of This Week’s Losses as US Shutdown Seems Averted - TradingView
Stocks Rally as US Government Shutdown Risks Recede - TradingView
Tariff Worries Pressure Stocks - TradingView
Tariff Worries Sink Stocks - TradingView
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of STTK, RIVN and FB - ACCESS Newswire
Shattuck Labs Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Shattuck Labs (STTK) to Release Earnings on Thursday - Defense World
CLVT, SLI & STTK: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Upcoming Class Actions Deadlines and Encourages Shareholders to Contact the Firm - ACCESS Newswire
Shattuck Labs (STTK) Projected to Post Earnings on Wednesday - MarketBeat
Shattuck Labs reports positive preclinical SL-325 data By Investing.com - Investing.com Nigeria
Shattuck Labs reports positive preclinical SL-325 data - Investing.com
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at ... - The Bakersfield Californian
Breakthrough in IBD Treatment? Shattuck's Novel DR3 Blocker Achieves Perfect Safety Score - StockTitan
Shattuck Labs (STTK) Expected to Announce Earnings on Wednesday - Defense World
GoHealth to Announce Fourth Quarter 2024 Results on February 27, 2025 - The Manila Times
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Revolutionary IBD Drug Development: Shattuck Labs Unveils Critical DR3 Antibody Results at ECCO 2025 - StockTitan
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights - br.ADVFN.com
Anti-DR3 antibody demonstrates efficacy in the treatment of IBD - BioWorld Online
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress - The Manila Times
Skye Bioscience Announces Participation in February Conferences - The Manila Times
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis Congress - Nasdaq
Pivotal IBD Drug Development: Shattuck Labs Reveals SL-325 Data at Major Crohn's Congress - StockTitan
JPMorgan Chase & Co. Grows Position in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Natera Announces National Commercial Coverage for its Fetal RhD NIPT - BioSpace
Planet Image International Leads 3 US Penny Stocks To Consider - Simply Wall St
Cresco Labs (OTCMKTS:CRLBF) Trading 2.1% Higher – What’s Next? - Defense World
Vizient Forecasts a 3.84% Rise in Pharmacy Spending - BioSpace
Finanzdaten der Shattuck Labs Inc-Aktie (STTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Shattuck Labs Inc-Aktie (STTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | Director |
Dec 04 '24 |
Sale |
1.25 |
133,371 |
166,714 |
5,406,353 |
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):